Lenalidomide-5-Br 3-(5-Bromo-1-oxoisoindolin-2-yl-piperidine-2-6-dione) is a derivative of lenalidomide, which is a medication used to treat multiple myeloma and myelodysplastic syndromes. Lenalidomide-5-Br is currently being researched as a potential treatment for these and other conditions.
Chemical name: (S)-3-(5-bromo-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione Molecular formula: C15H14BrN3O3 Formula weight: 379.19 g/mol CAS No: 1010100-26-1
Top ten keywords from Google and Synonyms:
Health benefits of this product: Lenalidomide-5-Br is being researched as a potential treatment for multiple myeloma, myelodysplastic syndromes, and other cancers. It works by targeting certain pathways in the immune system that are involved in cancer growth and progression. Early studies have shown promising results, but more research is needed to determine the full extent of its health benefits.
Potential effects: Lenalidomide-5-Br has similar potential effects to lenalidomide, which is an immunomodulatory drug that can slow or stop the growth of cancer cells. It works by enhancing the activity of T-cells and natural killer cells, which are part of the immune system's response to cancer. It can also help to reduce inflammation and improve the function of bone marrow. However, lenalidomide-5-Br may have different effects due to the addition of the bromine atom.
Product mechanism: The exact mechanism of action for lenalidomide-5-Br is not fully understood, but it is believed to work similarly to lenalidomide. It targets the immune system pathways involved in cancer growth and progression, including cytokines and angiogenic factors. By enhancing the immune response to cancer cells, lenalidomide-5-Br can slow or stop cancer growth.
Safety: As lenalidomide-5-Br is still being researched, there is limited information on its safety profile. However, it is likely to have a similar safety profile to lenalidomide, which can cause serious side effects such as blood clots, infections, and birth defects. It should not be taken during pregnancy, and caution must be exercised when prescribing and using it.
Side effects: Common side effects of lenalidomide-5-Br may include fatigue, nausea, diarrhea, and constipation. More serious side effects, such as blood clots, infections, and liver damage, are rare but can occur. Lenalidomide-5-Br may also increase the risk of birth defects if taken during pregnancy.
Dosing information: As lenalidomide-5-Br is still being researched, there is limited information on dosing. However, early studies suggest it may be effective at lower doses than lenalidomide. It should always be taken as directed by a healthcare professional.
Conclusion: Lenalidomide-5-Br is a derivative of lenalidomide that is being researched as a potential treatment for multiple myeloma, myelodysplastic syndromes, and other cancers. Its mechanism of action is believed to be similar to lenalidomide, with the potential for enhanced immune response to cancer cells. While research into the health benefits of lenalidomide-5-Br is ongoing, it appears to have a similar safety profile to lenalidomide, with the potential for serious side effects such as blood clots and infections. If you are experiencing multiple myeloma, myelodysplastic syndromes, or another condition that may benefit from lenalidomide-5-Br, speak to your healthcare professional about whether it may be an appropriate treatment option for you
